Original Research J Clin Psychiatry September 2026

Evaluation of Sexual Function With Adjunctive Lumateperone in Patients With Major Depressive Disorder

JCP 2026;87(3):10.4088/JCP.26m16387

Full Article Read the complete peer-reviewed article in J Clin Psychiatry. Clinical Summary Sexual dysfunction is common in major depressive disorder, often worsens with antidepressant therapy, and can drive nonadherence and discontinuation. For patients with inadequate antidepressant response, clinicians need adjunctive options that improve depressive symptoms without adding sexual adverse effects. FAQ Did adjunctive lumateperone improve sexual function in adults with major depressive disorder who had an inadequate antidepressant response?

Key Takeaways Baseline sexual dysfunction was common despite ongoing antidepressant therapy, affecting 82.5% of the overall sample, including 85.0% of women and 76.7% of men; this supports routine sexual-function assessment in patients with major depressive disorder who report inadequate antidepressant response. Clinical Guide How should clinicians assess sexual dysfunction in adults with major depressive disorder who report inadequate antidepressant therapy response? Clinical Guide How can clinicians decide whether adjunctive lumateperone is a reasonable option for patients with major depressive disorder, inadequate antidepressant response, and concern about sexual dysfunction?